Stocktoria
Torrent Pharmaceuticals Limited TORNTPHARM.NS
IN · National Stock Exchange of India · XNSE · stock · Healthcare · website
Torrent Pharmaceuticals Limited financials (annual)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ₹137.5B | ₹113.2B | ₹105.6B | ₹94.6B |
| Gross profit | ₹102.3B | ₹84.3B | ₹77.7B | ₹66.4B |
| R&D expense | ₹449.5M | ₹304.2M | ₹247.3M | ₹312.7M |
| SG&A expense | ₹23.9B | ₹20.0B | ₹19.0B | ₹16.4B |
| Operating income | ₹34.4B | ₹29.3B | ₹25.7B | ₹21.4B |
| Interest expense | ₹3.8B | ₹2.5B | ₹3.5B | ₹3.3B |
| Income tax | ₹7.3B | ₹7.6B | ₹7.0B | ₹6.0B |
| Net income | ₹21.6B | ₹19.1B | ₹16.6B | ₹12.5B |
| EPS (diluted) | — | ₹56.47 | ₹48.94 | ₹36.79 |
| Operating cash flow | ₹30.2B | ₹25.9B | ₹32.7B | ₹23.7B |
| Free cash flow | ₹23.5B | ₹19.7B | ₹28.3B | ₹17.9B |
| Cash & equivalents | ₹11.2B | ₹5.7B | ₹8.4B | ₹5.1B |
| Inventory | ₹31.4B | ₹25.4B | ₹22.8B | ₹22.3B |
| Goodwill | ₹39.9B | ₹3.4B | ₹3.4B | ₹3.4B |
| Total assets | ₹443.1B | ₹149.9B | ₹150.6B | ₹150.1B |
| Total debt | ₹150.3B | ₹32.0B | ₹40.2B | ₹53.7B |
| Total liabilities | ₹267.3B | ₹74.0B | ₹82.0B | ₹88.1B |
| Shareholders' equity | ₹83.9B | ₹75.9B | ₹68.6B | ₹62.0B |
Growth · year-over-year · Revenue CAGR 13.3%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | +21.5% | +7.1% | +11.6% | — |
| Net income growth | +13.2% | +15.4% | +33.0% | — |
| EPS growth | — | +15.4% | +33.0% | — |
| Free cash flow growth | +18.9% | -30.4% | +57.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · IN · as of 2026-03-31. Figures in INR. Facts plus Stocktoria's own computed scores — not investment advice.